P2RX7 and colitis: Using this strategy to express nanobody-based biologics targeting P2X7, we have demonstrated beneficial effects of a P2X7-blocking biologic on DSS-induced colitis, with a reduction of clinical symptoms, colon histopathology as well as reduced expression of chemokines and proinflammatory cytokines.